Get the Stockscreener App
87.17
1.34%
1.15
Pre-market:
87.28
0.11
+0.13%
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Medtronic Plc stock is traded at $87.17, with a volume of 8.20M.
It is up +1.34% in the last 24 hours and up +5.05% over the past month.
One of the largest medical-device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, transcatheter heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company primarily markets its products to healthcare institutions and physicians in the United States, Western Europe, and Japan. Foreign sales account for roughly 50% of the company's total sales.
See More
Previous Close:
$86.02
Open:
$86.65
24h Volume:
8.20M
Relative Volume:
1.07
Market Cap:
$112.76B
Revenue:
$33.54B
Net Income/Loss:
$4.66B
P/E Ratio:
24.08
EPS:
3.62
Net Cash Flow:
$5.19B
1W Performance:
+1.41%
1M Performance:
+5.05%
6M Performance:
+9.13%
1Y Performance:
+10.75%
1-Day Range:
$86.18
$87.41
1-Week Range:
$84.94
$87.41
52-Week Range:
$75.96
$96.25
Medtronic Plc Stock (MDT) Company Profile
Name
Medtronic Plc
Sector
Industry
Phone
01135314381700
Address
BUILDING TWO PARKMORE BUSINESS PARK WEST, GALWAY
Compare MDT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MDT
Medtronic Plc
|
87.17 | 112.76B | 33.54B | 4.66B | 5.19B | 3.62 |
|
ABT
Abbott Laboratories
|
136.01 | 233.36B | 42.34B | 13.50B | 6.66B | 7.71 |
|
BSX
Boston Scientific Corp
|
107.41 | 147.06B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
395.63 | 145.64B | 23.22B | 2.86B | 3.58B | 7.40 |
|
EW
Edwards Lifesciences Corp
|
78.21 | 44.46B | 5.54B | 4.18B | 623.10M | 7.00 |
Medtronic Plc Stock (MDT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-16-25 | Initiated | Leerink Partners | Outperform |
| Mar-04-25 | Upgrade | Citigroup | Neutral → Buy |
| Oct-10-24 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Aug-21-24 | Reiterated | Oppenheimer | Perform |
| Aug-15-24 | Upgrade | UBS | Sell → Neutral |
| Aug-14-24 | Downgrade | Stifel | Buy → Hold |
| May-30-24 | Initiated | Goldman | Sell |
| Jul-19-23 | Initiated | Robert W. Baird | Neutral |
| Jun-30-23 | Initiated | CL King | Buy |
| May-30-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Apr-24-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-29-23 | Downgrade | UBS | Buy → Sell |
| Jan-09-23 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-23-22 | Downgrade | Citigroup | Buy → Neutral |
| Nov-23-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Nov-16-22 | Downgrade | Deutsche Bank | Buy → Hold |
| Oct-18-22 | Initiated | Barclays | Equal Weight |
| Oct-13-22 | Initiated | Mizuho | Buy |
| Oct-12-22 | Initiated | Jefferies | Hold |
| Aug-24-22 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jul-06-22 | Initiated | Wolfe Research | Underperform |
| Jun-01-22 | Downgrade | Atlantic Equities | Overweight → Neutral |
| May-27-22 | Downgrade | Needham | Buy → Hold |
| Apr-13-22 | Downgrade | Truist | Buy → Hold |
| Mar-02-22 | Resumed | BofA Securities | Buy |
| Jan-10-22 | Downgrade | BTIG Research | Buy → Neutral |
| Jan-07-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jan-04-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-17-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-16-21 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Dec-10-21 | Initiated | RBC Capital Mkts | Outperform |
| Jun-10-21 | Resumed | Cowen | Outperform |
| May-25-21 | Initiated | Barclays | Equal Weight |
| Apr-15-21 | Initiated | Atlantic Equities | Overweight |
| Dec-15-20 | Upgrade | Goldman | Sell → Neutral |
| Dec-15-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-08-20 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Oct-08-20 | Upgrade | Stifel | Hold → Buy |
| Sep-11-20 | Initiated | Wolfe Research | Peer Perform |
| May-14-20 | Downgrade | DZ Bank | Buy → Hold |
| Mar-30-20 | Downgrade | Needham | Strong Buy → Buy |
| Mar-25-20 | Upgrade | DZ Bank | Hold → Buy |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Feb-13-20 | Initiated | Goldman | Sell |
| Jan-08-20 | Initiated | SunTrust | Buy |
| Jan-02-20 | Upgrade | Guggenheim | Neutral → Buy |
| Jun-05-19 | Upgrade | Wells Fargo | Market Perform → Outperform |
| Feb-04-19 | Reiterated | Needham | Strong Buy |
| Jan-03-19 | Initiated | Deutsche Bank | Buy |
| Jan-02-19 | Downgrade | Citigroup | Buy → Neutral |
| Dec-19-18 | Upgrade | JP Morgan | Neutral → Overweight |
| Nov-28-18 | Initiated | UBS | Buy |
| Oct-16-18 | Initiated | Barclays | Overweight |
| Aug-27-18 | Reiterated | Argus | Buy |
View All
Medtronic Plc Stock (MDT) Latest News
Medtronic Diabetes and tennis pro Alexander Zverev join forces to champion life without limits for people with diabetes - Medtronic
Medtronic training pact includes Hugo robot, cardiac ablation tech - MedTech Dive
Medtronic stock has significant opportunity in renal denervation, RBC says By Investing.com - Investing.com UK
FDA Clears Minimally Invasive Laser Ablation System from Medtronic for Epilepsy & Brain Tumors - Medical Device and Diagnostic industry
Medtronic partners with IRCAD on Hugo, Affera surgical training - MassDevice
Medtronic to invest $50 million over five years in Pune GCC - BusinessLine
Medtronic : IRCAD North America and Medtronic announce collaboration to advance surgical training and innovation - MarketScreener
Surgical Retractors Market Top Companies StudyMedtronic Plc, - openPR.com
Medtronic to invest $50 million over 5 years in Pune - PUNE PULSE
Medtronic plc Stock MDT Using Cash Flow Model NYSE Composite - Kalkine Media
A Look At The Fair Value Of Medtronic plc (NYSE:MDT) - simplywall.st
Medtronic to invest $50 million over 5 years in New Diabetes Global Capability Centre in Pune - Punekar News
Medtronic Invests $50M in Pune Diabetes Center - Rediff MoneyWiz
Leerink starts coverage on Boston Scientific and Medtronic with bullish ratings - Investing.com Nigeria
Leerink starts coverage on Boston Scientific and Medtronic with bullish ratings By Investing.com - Investing.com South Africa
Leerink Partners Initiates Coverage on Medtronic (MDT) with Outperform Rating | MDT Stock News - GuruFocus
Medtronic (MDT) Positioned for Growth Amid Strategic Shifts | MDT Stock News - GuruFocus
Leerink Partners Initiates Medtronic at Outperform With $110 Price Target - MarketScreener
Medtronic: Solid Recent Performance But Better Options Available (NYSE:MDT) - Seeking Alpha
Medtronic Doubles Down on Innovation as Cardiovascular Tech Takes Center Stage! - Smartkarma
Medtronic’s SWOT analysis: stock outlook amid diabetes spin-off and RDN growth - Investing.com
Medtronic separate diabetes business to be called MiniMed - MSN
Limited Impact On Intuitive Surgical From Reprocessed Robotic Instruments: Analyst - Benzinga
FDA approves Medtronic Omniasecure defib lead - BioWorld MedTech
Medtronic Plc. (NYSE: MDT) To Separate Its Diabetes Business - Smartkarma
Earnings Preview: What To Expect From Medtronic’s Report - MSN
Medtronic Diabetes Spinoff to Honor MiniMed Roots - Medical Device and Diagnostic industry
Medtronic (MDT) Revives MiniMed for Diabetes Spin-Off - GuruFocus
Medtronic recalls ventilators linked to 2 serious injuries, 1 death - MedTech Dive
Medtronic issues safety notice for Hugo surgical robot console in Europe - MassDevice
Medtronic announces MiniMed as name for planned New Diabetes Company - GuruFocus
Medtronic (MDT) Unveils "MiniMed" for Upcoming Diabetes Spinoff - GuruFocus
Medtronic's New Diabetes Company to Be Named MiniMed - MarketScreener
Medtronic announces MiniMed as name for planned New Diabetes Company | MDT Stock News - GuruFocus
Medtronic names planned diabetes spinoff company MiniMed - Investing.com
Medtronic names planned diabetes spinoff company MiniMed By Investing.com - Investing.com Canada
Medtronic Announces MiniMed As Name For Planned New Diabetes Company - marketscreener.com
FDA Upgrades Medtronic Recall Of Newport Ventilators To Class I - RTTNews
Medtronic Q4 Earnings and Revenues Top, Stock Down in Pre-market - MSN
Medtronic advises discontinuation of certain Newport ventilators after recall - MassDevice
Medtronic : announces voluntary recall of select Newport™ HT70 and Newport™ HT70 Plus ventilators and certain related Newport™ service parts - marketscreener.com
Medtronic : treats first U.S. patient in Global SYMPLICITY Registry DEFINE Study - marketscreener.com
5 Things You Need to Know If You Buy Medtronic Today - The Motley Fool
Medtronic names Kate Benedict president of acute care and monitoring - MedTech Dive
Medtronic appoints new president of Acute Care & Monitoring unit - MassDevice
Medtronic Announces Intent To Spin Diabetes Business - Forbes
Medtronic wins CE mark for VitalFlow ECMO system - MassDevice
Medtronic to separate diabetes business, WSJ reports - MSN
Medtronic's Separation of Diabetes Business May Drive Long-Term Value, Needham Says - marketscreener.com
Medtronic removes tracheostomy tubes due to dislodging risk - MedTech Dive
NEEDHAM ANALYST MAINTAINS HOLD RATING ON MEDTRONIC STOCK By Investing.com - Investing.com UK
Medtronic Plc Stock (MDT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Medtronic Plc Stock (MDT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Walter Matthew R. | SVP, Chief HR Officer |
Jan 27 '25 |
Option Exercise |
74.84 |
1,337 |
100,061 |
26,997 |
| Marinaro Michael | EVP & President, Surgical OU |
Jan 27 '25 |
Option Exercise |
74.84 |
2,345 |
175,500 |
43,323 |
| Martha Geoffrey | Chairman and CEO |
Jan 27 '25 |
Option Exercise |
74.84 |
34,741 |
2,600,016 |
216,954 |
| Wall Brett A. | EVP & Pres Neuroscience |
Jan 24 '25 |
Option Exercise |
78.00 |
12,437 |
970,086 |
53,416 |
| Wall Brett A. | EVP & Pres Neuroscience |
Jan 24 '25 |
Sale |
90.00 |
12,437 |
1,119,330 |
40,979 |
0.53%
0.42%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):